|
|
Vaccine Detail
|
MERS England1 S DNA vaccine |
| Vaccine Information |
- Vaccine Name: MERS England1 S DNA vaccine
- Target Pathogen: MERS-CoV
- Target Disease: Middle East Respiratory Syndrome (MERS)
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse, rhesus monkey
- Antigen: S from MERS-CoV (Wang et al., 2015)
- S from MERS-CoV
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: A DNA vaccine constructed from a plasmid vaccines that encoded full-length, membrane-anchored Spike protein. VRC8400 plasmid used to construct antigen (Wang et al., 2015)
|
| Host Response |
|
Mouse Response
- Host Strain: BALB/cJ
- Host age: 6-8 weeks (Wang et al., 2015)
- Host gender: Female (Wang et al., 2015)
- Vaccination Protocol: immunized with plasmid DNA at weeks 0, 3, and 6 (Wang et al., 2015)
- Immune Response: high titers of neutralizing antibody (Wang et al., 2015)
|
| References |
Wang et al., 2015: Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nature communications. 2015; 6; 7712. [PubMed: 26218507].
|
|
